Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The protections extend through at least 2035, with the potential for further extensions
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
Subscribe To Our Newsletter & Stay Updated